Gelesis Holdings Price to Sales Ratio 2021-2022 | GLS

Historical PS ratio values for Gelesis Holdings (GLS) over the last 10 years. The current P/S ratio for Gelesis Holdings as of June 28, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gelesis Holdings P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-06-28 1.54 12.86
2022-03-31 4.53 $0.12 37.83
2021-12-31 9.96 $0.55 17.95
2021-09-30 9.92 $0.55 17.88
2021-06-30 9.79 $0.55 17.65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00